Biocon Biologics
Working at Biocon Biologics
Company Summary
Overall Rating

8% below

Critically rated for
Promotions, Work satisfaction, Work-life balance
Work Policy




Top Employees Benefits
About Biocon Biologics

Biocon Biologics is driven by a strong sense of purpose and the unwavering commitment to serve patients and healthcare systems across the globe by unlocking equitable access to high quality biosimilars.
Healthcare systems across the world are skewed towards serving the affluent, denying access to many. Biocon Biologics is challenging the status quo by putting ‘patients first’ to make a long-term social impact worldwide.
We are leveraging our affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as improve patient outcomes and provide global communities with differentiated, high-quality and affordable healthcare solutions.
Our business model seeks to make biologic therapies affordable, accessible and available to all, thereby benefiting patients and their families across the world.
Our roadmap for the future is to enable a healthier world.
Biocon Biologics Ratings
Overall Rating
Category Ratings
Company culture
Skill development
Job security
Salary
Work-life balance
Work satisfaction
Promotions
Work Policy at Biocon Biologics
Biocon Biologics Reviews
Top mentions in Biocon Biologics Reviews
Compare Biocon Biologics with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 3.6/5 based on 814 reviews | 3.9/5 based on 1.4k reviews | 3.9/5 based on 1.1k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | No highly rated category | Work-life balance Company culture Skill development | Skill development Work-life balance Salary | Skill development Work-life balance Salary |
Critically Rated for | Promotions Work satisfaction Work-life balance | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 77% employees reported | Work from office 86% employees reported | Work from office 75% employees reported | - |
Rating by Women Employees | 3.4 Average rated by 152 women | 3.5 Good rated by 113 women | 3.6 Good rated by 90 women | - no rating available |
Rating by Men Employees | 3.6 Good rated by 632 men | 3.9 Good rated by 1.2k men | 3.9 Good rated by 950 men | - no rating available |
Job security | 3.3 Average | 3.6 Good | 3.8 Good | 4.0 Good |
Biocon Biologics Salaries
Deputy Manager
Senior Scientist
Junior Executive
Principal Scientist
Executive Production
Scientist
Territory Business Manager
Associate Director
Executive Engineer
QC Executive
Biocon Biologics Interview Questions
Interview questions by designation
Top Biocon Biologics interview questions and answers
Biocon Biologics Jobs
Biocon Biologics News
Stocks that will see action today: 25 February 2025
- Torrent Power's arm, Torrent Green Energy, has incorporated Torrent Urja 32 Pvt Ltd (TU32) to generate electricity from renewable energy.
- IREDA has received approval from its shareholders to raise up to ₹5,000 crore through issuance of equity shares to qualified institutional buyers.
- Life Insurance Corporation of India (LIC) has been slapped with a demand notice of about Rs 57.2 crore for excess Input Tax Credit (ITC) availed.
- Biocon Biologics has launched a biosimilar product to treat certain autoimmune diseases in the US market.

Biocon Biologics sees diversified global expansion offsetting US localisation risks
- Biocon Biologics believes that its diversified global expansion will offset the risks of US localization.
- The company has witnessed sustained growth in the Mediterranean and UK-Nordics clusters, as well as positive traction in Japanese and Australian markets.
- Biocon Biologics aims to bring affordability and broaden access to patients in America, aligning with the US administration's focus on lowering healthcare costs.
- Biocon Biologics reported a 14% YoY growth in revenue for the Biosimilars segment and maintained stable market shares in Europe.

CCI slaps ₹40 lakh fine on Goldman Sachs for failure to notify investment in Biocon Biologics
- Goldman Sachs has been fined ₹40 lakh by CCI for failure to notify its investment in Biocon Biologics.
- Goldman Sachs made the investment without seeking CCI approval, violating the Competition Act.
- CCI found that the investment granted Goldman Sachs strategic rights beyond those of ordinary shareholders.
- The ruling highlights the importance of compliance with competition laws in structuring minority investments.
Biocon Biologics’ Bengaluru Facilities Get VAI Tag From US Drug Regulator
- The USFDA has issued a 'voluntary action indicated' (VAI) tag to Biocon Biologics' manufacturing facilities in Bengaluru.
- The inspection was carried out between July 15 and July 26 to assess good manufacturing practices.
- Objectionable conditions were found, but no administrative or regulatory action was recommended.
- Biocon Biologics remains committed to global standards of quality and compliance.

Biocon Biologics Confident Of Tackling Pricing Pressures, Ready To Compete
- Biocon Biologics' Chief Executive Officer and Managing Director Shreehas Tambe is confident of tackling pricing pressures in the biosimilar market.
- Tambe emphasized that pricing is not a challenge for them, but rather a differentiator due to their competitive setup and cost structure.
- Biocon Biologics, as an emerging markets' player, focuses on a frugal cost structure and affordability index, driving the company's growth.
- Biocon Ltd., the parent company of Biocon Biologics, reported an over 84% decline in profit for the September quarter, while biosimilar sales were up 4%.

Biocon Biologics Offices
Compare Biocon Biologics with




















Contribute & help others!
Companies Similar to Biocon Biologics












Biocon Biologics FAQs
Reviews
Interviews
Salaries
Users/Month